Peptides for Women: The Research Across Menopause, Fertility, Skin, and Bone

References that linked to unrelated papers have been corrected to identify the relevant studies. This citation correction does not constitute a full clinical review of the article.

Most peptide content online is written by men, for men. The biohacking and peptide therapy communities skew heavily male, and dosing protocols, use case discussions, and safety considerations are often framed around male physiology. But women represent the majority of participants in many landmark peptide trials — 74% of the STEP 1 semaglutide trial and 67% of the SURMOUNT-1 tirzepatide trial were women.

This creates a disconnect: the clinical evidence often includes robust female data, but the community discussion rarely reflects it. This article focuses specifically on peptides that have been studied in women, with attention to gender-specific efficacy, safety considerations, and use cases.

Bremelanotide (brand name Vyleesi) is the only peptide FDA-approved specifically for a women's health indication — hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT Phase 3 trials enrolled approximately 1,247 women and demonstrated statistically significant improvements in both sexual desire and associated distress.

Unlike flibanserin (Addyi), which requires daily dosing and has alcohol restrictions, bremelanotide is used on-demand via subcutaneous injection before anticipated sexual activity. The mechanism is central — it activates melanocortin-4 receptors in the brain, stimulating dopaminergic and oxytocinergic pathways rather than working through peripheral blood flow like PDE5 inhibitors.

The primary side effect is nausea, occurring in roughly 40% of patients, though it typically decreases with subsequent doses. Bremelanotide should not be used more than once in 24 hours or more than 8 times per month.

The GLP-1 agonist weight loss trials have produced some of the strongest peptide data in predominantly female populations. The STEP 1 trial (semaglutide 2.4mg) enrolled approximately 74% women and showed 14.9% mean body weight loss at 68 weeks. The SURMOUNT-1 trial (tirzepatide) enrolled approximately 67% women and showed up to 20.9% weight loss at the highest dose.

Subgroup analyses from both programs show consistent efficacy across sexes — women respond as well as men to GLP-1 therapy. The side effect profile is also similar, with nausea being the most common complaint during dose escalation.

An important safety consideration: semaglutide requires discontinuation at least 2 months before planned conception due to insufficient pregnancy safety data. This applies to all GLP-1 agonists. Women of childbearing age should use reliable contraception during treatment.

GHK-Cu (copper peptide) may be the most widely used peptide by women, primarily through topical skincare products. It has a reasonable evidence base for skin rejuvenation — stimulating collagen synthesis (types I and III), glycosaminoglycan production, and fibroblast activity.

What makes GHK-Cu particularly relevant for women: plasma levels decline approximately 60% from age 20 to 60 (from roughly 200 ng/mL to 80 ng/mL), and this decline correlates with visible skin aging. A 2018 review found that GHK-Cu modulates expression of over 4,000 human genes, resetting gene expression patterns toward a healthier state.

Topical GHK-Cu is available over the counter with an excellent safety profile. Injectable GHK-Cu for systemic anti-aging effects has less human data but is increasingly discussed in the longevity community. For women seeking evidence-based peptide skincare, GHK-Cu has one of the strongest rationales.

Kisspeptin is the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal cascade that controls reproductive function. It has a uniquely promising application in fertility medicine: as a safer trigger for oocyte maturation in IVF cycles.

A landmark clinical trial showed that kisspeptin-54 effectively triggered egg maturation in IVF patients with zero cases of ovarian hyperstimulation syndrome (OHSS), compared to the 1-5% OHSS risk with standard hCG triggers. OHSS is a serious, potentially life-threatening complication of IVF, making a safer alternative genuinely significant.

Beyond IVF, kisspeptin is being studied for hypothalamic amenorrhea (loss of menstrual periods due to stress, low body weight, or excessive exercise) and as a diagnostic tool for disorders of puberty. This is one of the few peptide research areas where women's health is the primary focus rather than an afterthought.

Most peptides have not been specifically studied in pregnant or breastfeeding women, and should generally be avoided during pregnancy. Specific considerations:

GLP-1 agonists (semaglutide, tirzepatide): Discontinue at least 2 months before planned conception. Animal data shows reproductive toxicity at high doses.

Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin): May affect menstrual cycle regularity. Women should monitor cycle changes and report to their clinician.

Kisspeptin and gonadorelin: Directly affect reproductive hormones — use requires careful clinical oversight, especially in women of reproductive age.

Bromelanotide (PT-141): Contraindicated in uncontrolled hypertension. Blood pressure monitoring is recommended.

Topical peptides (GHK-Cu, SNAP-8, Argireline): Generally considered safe for women, including during pregnancy, though data is limited.

The bottom line: women should work with clinicians experienced in peptide therapy who understand gender-specific pharmacology, hormonal interactions, and reproductive considerations.